Abdullaev R Iu, Vaniev E V, Kaminskaia G O, Vasil'eva I A, Komissarova O G
Probl Tuberk Bolezn Legk. 2009(2):57-61.
The frequency and magnitude of hepatotoxic reactions were compared in 147 new cases of pulmonary tuberculosis within the first three months of chemotherapy (CT) by standard regimen 1 [H, R, Z, S (E)] (Group 1) and regimen 2B [the same drugs + kanamycin (amikacin) and fluoroquinolones] (Group 2). Their efficiency was evaluated from 6 serum indices--the level of bilirubin, the activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), and gamma-glutamyl transpeptidase (GGTP), and thymol test results. Tests were monthly carried out. The results were separately analyzed in patients with and without baseline abnormalities in the indices being tested. Within the first two months of CT, the patients without baseline abnormalities showed the slightly higher frequency and magnitude of hepatotoxic reactions on receiving regimen 2B. Following 3 months of CT combined with hepatoprotectors, the patients treated by standard regimen 1 had solitary laboratory signs of hepatic damage, but there was a regular elevation of GGTP in the regimen 2B group. After a month of regimen 1 CT in combination with hepatoprotectors, the patients with baseline abnormalities has positive changes in all the studied indices. In the patients treated by regimen 2B in combination with hepatoprotectors, the changes were the same, except for GGTP that remained to be at the increased baseline levels. Following 2 months of CT, in Group 1 positive changes continued in the studied markers and, with regimen 2B treatment, abnormal changes began increasing again. After 3 months abnormal changes were single in the markers of hepatic damage with regimen 1 treatment and there was a repeated significant rise in the values of AP and GGTP with regimen 2B. It is concluded that in addition to ALT and AST, GGTP is of great informative value in controlling the hepatotoxic effects of CT.
采用标准方案1[H、R、Z、S(E)](第1组)和方案2B[相同药物+卡那霉素(阿米卡星)和氟喹诺酮类药物](第2组),对147例化疗(CT)前三个月内的新发肺结核病例的肝毒性反应频率和严重程度进行了比较。从6项血清指标评估其疗效,即胆红素水平、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(AP)、γ-谷氨酰转肽酶(GGTP)的活性以及麝香草酚试验结果。每月进行检测。对检测指标有或无基线异常的患者分别进行结果分析。在CT的前两个月内,检测指标无基线异常的患者在接受方案2B治疗时肝毒性反应的频率和严重程度略高。CT联合肝保护剂治疗3个月后,采用标准方案1治疗的患者有孤立的肝损伤实验室指标,但方案2B组的GGTP有规律性升高。采用方案1联合肝保护剂进行CT治疗1个月后,有基线异常的患者所有研究指标均有阳性变化。采用方案2B联合肝保护剂治疗的患者,除GGTP仍维持在升高的基线水平外,变化相同。CT治疗2个月后,第1组研究指标持续出现阳性变化,而采用方案2B治疗时,异常变化又开始增加。3个月后,采用方案1治疗时肝损伤指标的异常变化为单个,而采用方案2B治疗时,AP和GGTP值再次显著升高。结论是,除ALT和AST外,GGTP在控制CT的肝毒性作用方面具有重要的信息价值。